Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05381103 · ClinicalTrials.gov registry record · Phase 2
PSMA-PET to Guide Prostatectomy
A Phase 2 study of Prostate Cancer, sponsored by Five Eleven Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 288
- Enrollment target
- 1
- Study location
NCT05381103 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Five Eleven Pharma. The registered enrollment target is 288 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05381103, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Five Eleven Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 288 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, 196 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount pathology. Pre-surgical imaging findings will also be evaluated in the context of affecting subsequent surgical plans and impacting actual patient outcomes.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PSMA-PET and SOC MRI
- DIAGNOSTIC_TEST SOC MRI
Study Locations (1)
Indiana
- Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05381103
The ClinicalTrials.gov registry entry for NCT05381103 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (53% lower). The listed sponsor is Five Eleven Pharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which PSMA-PET and SOC MRI is the first listed.
NCT05381103 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT05381103 about?
NCT05381103 is a clinical study titled "PSMA-PET to Guide Prostatectomy". In this study, 196 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount pathology. Pre-surgical imaging findings will also be evaluate...
What is the current status of trial NCT05381103?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 288 participants. The study started on 2021-10-01. Estimated completion is 2028-12-01.
What conditions does trial NCT05381103 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05381103?
The interventions under investigation include: PSMA-PET and SOC MRI (DIAGNOSTIC_TEST), SOC MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05381103?
This trial is sponsored by Five Eleven Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05381103 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.